Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1971 1
1974 2
1977 3
1978 2
1979 2
1980 3
1981 4
1982 3
1983 5
1984 6
1985 8
1986 7
1987 12
1988 16
1989 15
1990 17
1991 14
1992 22
1993 23
1994 17
1995 12
1996 14
1997 14
1998 6
1999 13
2000 8
2001 15
2002 15
2003 18
2004 7
2005 12
2006 20
2007 21
2008 19
2009 17
2010 25
2011 18
2012 20
2013 29
2014 26
2015 28
2016 22
2017 17
2018 12
2019 14
2020 18
2021 16
2022 19
2023 18
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

643 results

Results by year

Filters applied: . Clear all
Page 1
Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM.
Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, Fernandes RA, Gomez AM, Nadj GS, Bartley CM, Schubert RD, Hawes IA, Vazquez SE, Iyer M, Zuchero JB, Teegen B, Dunn JE, Lock CB, Kipp LB, Cotham VC, Ueberheide BM, Aftab BT, Anderson MS, DeRisi JL, Wilson MR, Bashford-Rogers RJM, Platten M, Garcia KC, Steinman L, Robinson WH. Lanz TV, et al. Among authors: steinman l. Nature. 2022 Mar;603(7900):321-327. doi: 10.1038/s41586-022-04432-7. Epub 2022 Jan 24. Nature. 2022. PMID: 35073561 Free PMC article.
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC; ULTIMATE I and ULTIMATE II Investigators. Steinman L, et al. N Engl J Med. 2022 Aug 25;387(8):704-714. doi: 10.1056/NEJMoa2201904. N Engl J Med. 2022. PMID: 36001711 Clinical Trial.
Epstein-Barr virus and multiple sclerosis.
Robinson WH, Steinman L. Robinson WH, et al. Among authors: steinman l. Science. 2022 Jan 21;375(6578):264-265. doi: 10.1126/science.abm7930. Epub 2022 Jan 13. Science. 2022. PMID: 35025606 Free article.
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, Cohen JA. Cree BA, et al. Among authors: steinman l. Mult Scler. 2022 Oct;28(12):1944-1962. doi: 10.1177/13524585221102584. Epub 2022 Jun 28. Mult Scler. 2022. PMID: 35765217 Free PMC article. Clinical Trial.
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; SUNBEAM Study Investigators. Comi G, et al. Among authors: steinman l. Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3. Lancet Neurol. 2019. PMID: 31492651 Clinical Trial.
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; RADIANCE Trial Investigators. Cohen JA, et al. Among authors: steinman l. Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3. Lancet Neurol. 2019. PMID: 31492652 Clinical Trial.
T cell deletional tolerance restricts AQP4 but not MOG CNS autoimmunity.
Sagan SA, Moinfar Z, Moseley CE, Dandekar R, Spencer CM, Verkman AS, Ottersen OP, Sobel RA, Sidney J, Sette A, Anderson MS, Steinman L, Wilson MR, Sabatino JJ Jr, Zamvil SS. Sagan SA, et al. Among authors: steinman l. Proc Natl Acad Sci U S A. 2023 Jul 25;120(30):e2306572120. doi: 10.1073/pnas.2306572120. Epub 2023 Jul 18. Proc Natl Acad Sci U S A. 2023. PMID: 37463205 Free PMC article.
643 results